NHL
MCID: LYM143
MIFTS: 73

Lymphoma, Non-Hodgkin, Familial (NHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial 57 38 40
Non-Hodgkin Lymphoma 57 38 12 76 29 6 15
Lymphoma, Non-Hodgkin 57 13 73
Nhl 57 75
Lymphoma, Non-Hodgkin, Somatic 57
Lymphoma, Follicular, Somatic 57
Familial Non-Hodgkin Lymphoma 75
Non-Hodgkin Lymphoma; Nhl 57
Lymphoma Non-Hodgkins 55

Classifications:



External Ids:

OMIM 57 605027
Disease Ontology 12 DOID:0060060
MedGen 42 C0024305
ICD10 33 C85.7
UMLS 73 C0024305

Summaries for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot : 75 Familial non-Hodgkin lymphoma: Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary : Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to b-cell lymphomas and diffuse large b-cell lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are lymphoma and Reduced mammosphere formation

Disease Ontology : 12 A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Wikipedia : 76 Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except... more...

Description from OMIM: 605027

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 455)
# Related Disease Score Top Affiliating Genes
1 b-cell lymphomas 33.4 BCL10 BCL6 CCND1 CD5 IRF4 MS4A1
2 diffuse large b-cell lymphoma 33.4 BCL6 CD5 IRF4 MYC TP53
3 lymphoma, mucosa-associated lymphoid type 33.4 BCL10 BCL6 CCND1 CD5 IRF4
4 follicular lymphoma 33.2 BCL10 BCL6 CCND1 IRF4 MS4A1 MYC
5 richter's syndrome 33.2 CD5 IRF4 MYC TP53
6 anaplastic large cell lymphoma 32.9 ALK NPM1 PAX5 PTPRC
7 composite lymphoma 32.7 BCL6 CD5 PAX5
8 reticulosarcoma 32.7 ALK BCL6 NPM1 PAX5 PTPRC
9 plasmablastic lymphoma 32.7 BCL6 MS4A1 MYC PTPRC
10 follicular lymphoma 1 32.6 BCL10 BCL6
11 lymphoma, hodgkin, classic 31.8 ALK BCL6 CD5 PAX5 PTPRC
12 lymphocytic leukemia 31.8 CD5 MYC PAX5 TP53
13 leukemia, chronic lymphocytic 31.7 BCL10 BCL6 BRAF CCND1 CD5 MS4A1
14 lymphoma 31.7 ALK BCL10 BCL6 CASP10 CCND1 MYC
15 lymphosarcoma 31.7 BCL6 CD5 PTPRC
16 leukemia, chronic lymphocytic 2 31.7 BRAF NRAS TP53
17 primary mediastinal large b-cell lymphoma 31.4 BCL6 IRF4 MYC
18 myeloma, multiple 31.4 BRAF CCND1 IRF4 MYC NRAS PTPRC
19 hodgkin's lymphoma, lymphocytic-histiocytic predominance 31.3 BCL6 PTPRC
20 acquired immunodeficiency syndrome 31.1 BCL6 MYC TP53
21 leukemia, acute myeloid 31.0 MYC NPM1 NRAS PTPRC TP53
22 adenocarcinoma 30.9 ALK BRAF CCND1 MYC PIK3CA TP53
23 mantle cell lymphoma 30.9 BCL6 CCND1 CD5 MYC PAX5 PTPRC
24 hairy cell leukemia 30.9 BRAF CCND1 CD5
25 marginal zone b-cell lymphoma 30.9 BCL10 BCL6 CCND1 CD5 IRF4
26 thyroid cancer 30.8 BRAF CCND1 MYC NRAS PIK3CA TP53
27 burkitt lymphoma 30.8 BCL6 MS4A1 MYC PAX5
28 lymphoproliferative syndrome 30.7 CASP10 NRAS PRF1
29 pancreas adenocarcinoma 30.7 CCND1 MYC PIK3CA TP53
30 lymphoblastic lymphoma 30.7 BCL6 CD5 PTPRC
31 histiocytoma 30.7 ALK PTPRC TP53
32 gastric lymphoma 30.6 BCL10 BCL6 TP53
33 neuroblastoma 30.6 ALK MYC NRAS PIK3CA TP53
34 cll/sll 30.5 CCND1 CD5 PAX5 TP53
35 glioblastoma 30.5 ALK BRAF CCND1 MYC NRAS PIK3CA
36 brain cancer 30.5 ALK BRAF MYC NRAS PIK3CA TP53
37 lung cancer susceptibility 3 30.5 ALK BRAF CCND1 NRAS PIK3CA TP53
38 autoimmune lymphoproliferative syndrome 30.5 CASP10 NRAS PRF1 PTPRC
39 autoimmune lymphoproliferative syndrome, type v 30.5 ALK BCL6 CD5
40 small cell cancer of the lung 30.5 MYC PAX5 PIK3CA TP53
41 splenic marginal zone lymphoma 30.5 BCL6 CD5 PAX5
42 skin melanoma 30.5 BRAF NRAS TP53
43 cholangiocarcinoma 30.4 BRAF CCND1 PIK3CA TP53
44 prolymphocytic leukemia 30.4 CCND1 CD5 MYC
45 breast ductal carcinoma 30.4 CCND1 RAD54L TP53
46 peripheral t-cell lymphoma 30.4 ALK BCL6 CD5 MS4A1
47 primary effusion lymphoma 30.4 BCL6 IRF4 MYC
48 breast lymphoma 30.4 BCL6 CD5
49 plasma cell leukemia 30.4 CCND1 IRF4
50 nodular lymphocyte predominant hodgkin lymphoma 30.4 BCL6 PAX5

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:



Diseases related to Lymphoma, Non-Hodgkin, Familial

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Clinical features from OMIM:

605027

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

32
# Description HPO Frequency HPO Source Accession
1 lymphoma 32 HP:0002665

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.5 BCL6 BRAF CCND1 CD5 MYC NRAS
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BCL10 RAD54B RAD54L TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BCL10 BRAF CCND1 MYC RAD54B RAD54L

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 BCL10 BCL6 BRAF CCND1 IRF4 MYC
2 hematopoietic system MP:0005397 10.41 BCL10 BCL6 BRAF CCND1 CD5 IRF4
3 immune system MP:0005387 10.38 BCL10 BCL6 BRAF CCND1 CD5 IRF4
4 growth/size/body region MP:0005378 10.34 ALK BCL6 BRAF CCND1 IRF4 MYC
5 homeostasis/metabolism MP:0005376 10.31 ALK BCL6 BRAF CCND1 IRF4 MYC
6 endocrine/exocrine gland MP:0005379 10.28 ALK BCL10 BCL6 BRAF CCND1 MYC
7 mortality/aging MP:0010768 10.28 ALK BCL10 BCL6 BRAF CCND1 MYC
8 integument MP:0010771 10.16 ALK BRAF CCND1 CD5 MYC NPM1
9 neoplasm MP:0002006 10.15 ALK BRAF CCND1 IRF4 MYC NPM1
10 nervous system MP:0003631 10.1 ALK BCL10 BRAF CCND1 CD5 MYC
11 liver/biliary system MP:0005370 10.03 BCL6 BRAF MYC NPM1 NRAS PRF1
12 normal MP:0002873 9.85 BCL6 BRAF CCND1 CD5 MYC NRAS
13 no phenotypic analysis MP:0003012 9.8 BCL6 CD5 MYC NRAS PIK3CA PTPRC
14 pigmentation MP:0001186 9.35 ALK BRAF MYC NRAS TP53
15 skeleton MP:0005390 9.28 ALK BRAF CCND1 MYC NRAS PAX5

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 445)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
8 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
12
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
13
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
14 Orange Approved Phase 3
15
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
16
Ofloxacin Approved Phase 3 82419-36-1 4583
17
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
18
Idarubicin Approved Phase 3 58957-92-9 42890
19
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
20
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
21
Bleomycin Approved, Investigational Phase 3,Phase 1,Phase 2 11056-06-7 5360373
22
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
23
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
25
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
26
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
27
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
28
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
29
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
30
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
31
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
32
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
33
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
34
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
35
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
36
rituximab Approved Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 174722-31-7 10201696
37
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
38
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
39
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
40
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
41
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Tazobactam Approved Phase 3 89786-04-9 123630
44
Vancomycin Approved Phase 3 1404-90-6 14969 441141
45
Piperacillin Approved Phase 3 66258-76-2 43672
46
Dalteparin Approved Phase 3 9005-49-6
47
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
48
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
49
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 51-75-2 4033
50
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2

Interventional clinical trials:

(show top 50) (show all 490)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
4 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
5 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
6 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
8 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
9 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
10 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
18 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
19 Combination Chemotherapy in Treating Patients With Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
20 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
21 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
22 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
23 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
24 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
25 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
26 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
27 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
28 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
29 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
30 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
31 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
32 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
33 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
34 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
35 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
36 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
37 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
38 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
39 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
40 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
41 Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation Terminated NCT00003056 Phase 3 cyclosporine;cyclosporine and methotrexate
42 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine
43 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
44 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
45 Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma Unknown status NCT00006669 Phase 2 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
46 Beta Alethine in Treating Patients With Low-Grade Lymphoma Unknown status NCT00007839 Phase 1, Phase 2 beta alethine
47 Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma Unknown status NCT00026429 Phase 2
48 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
49 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
50 Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00005959 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Genetic tests related to Lymphoma, Non-Hodgkin, Familial:

# Genetic test Affiliating Genes
1 Non-Hodgkin Lymphoma 29 BCL10 CASP10 PRF1 RAD54B RAD54L

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

MalaCards organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Breast, Nk Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 1992)
# Title Authors Year
1
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
2
Paraneoplastic pemphigus without detectable anti-plakin antibodies in a patient with non-Hodgkin lymphoma. ( 29143865 )
2018
3
Calciphylaxis in a Patient With Non-Hodgkin Lymphoma: Case Report and Literature Review. ( 29478335 )
2018
4
Primary Cardiac B-Non-Hodgkin Lymphoma Disguised as a Pacemaker Endocarditis. ( 29977733 )
2018
5
Second primary cutaneous T-cell lymphoma in patients with non-Hodgkin lymphoma: a chicken-or-the-egg issue. ( 29047113 )
2018
6
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( 29419687 )
2018
7
Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. ( 28332735 )
2018
8
Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma. ( 28679297 )
2018
9
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. ( 29978452 )
2018
10
Non-alcoholic Wernicke-Korsakoff syndrome heralding non-Hodgkin lymphoma progression. ( 29582179 )
2018
11
Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma? ( 29650494 )
2018
12
Herpes simplex reactivation after photodynamic therapy for actinic cheilitis in a patient with Non-Hodgkin Lymphoma: a possible indication for prophylaxis. ( 29512976 )
2018
13
Primary intestinal aspergillosis resulting in acute intestinal volvulus after autologous stem cell transplantation in a patient with relapsed non-Hodgkin lymphoma: report on a rare infectious complication and a review of the literature. ( 30238855 )
2018
14
Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma. ( 29469175 )
2018
15
Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. ( 30230156 )
2018
16
Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry. ( 28571522 )
2018
17
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. ( 30316785 )
2018
18
Hepatitis C-Associated B-cell Non-Hodgkin Lymphoma: A Pictorial Review. ( 30020272 )
2018
19
Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. ( 29252084 )
2018
20
Jejunal Intussusception: A Rare Manifestation of a Primary Thyroid Non-Hodgkin Lymphoma. ( 30079283 )
2018
21
Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma. ( 30548485 )
2018
22
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). ( 29673807 )
2018
23
Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. ( 29405071 )
2018
24
Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. ( 29561206 )
2018
25
Primary Non-Hodgkin Lymphoma of the Parotid Gland Masquerading Chronic Sialadenitis. ( 30507870 )
2018
26
Effect of PET/CT on the Management and Outcomes of Participants with Hodgkin and Aggressive Non-Hodgkin Lymphoma: A Multicenter Registry. ( 30511907 )
2018
27
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. ( 30520026 )
2018
28
Serological Assessment of 18 Pathogens and Risk for AIDS-associated Non-Hodgkin Lymphoma. ( 30531297 )
2018
29
Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma. ( 30543588 )
2018
30
Primary extra-nodal non-Hodgkin lymphoma in buttock soft tissue: A rare case report. ( 30544469 )
2018
31
Levels of regulatory T cells and invariant natural killer cells and their associations with regulatory B cells in patients with non-Hodgkin lymphoma. ( 30546901 )
2018
32
A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma. ( 30547695 )
2018
33
Cause-specific mortality among medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. ( 30548238 )
2018
34
A prospective, multicentre study of involved-field radiotherapy with autologous stem cell transplantation for patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma (ALLG HDNHL04/TROG 03.03). ( 30553941 )
2018
35
Letter to the editors regarding the paper: Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience. ( 30555526 )
2018
36
Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients. ( 30450652 )
2018
37
Expert opinion on managing chronic HCV in patients with non-Hodgkin lymphoma and other extrahepatic malignancies. ( 30451149 )
2018
38
Periportal hepatic involvement of non-Hodgkin lymphoma: a rare case report with magnetic resonance imaging findings. ( 30465451 )
2018
39
Molecular and cellular genetics of non-Hodgkin lymphoma: Diagnostic and prognostic implications. ( 30465756 )
2018
40
Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma. ( 30470842 )
2018
41
Reproductive factors, exogenous hormone use and risk of B-cell non-Hodgkin lymphoma in a cohort of women from the European Prospective Investigation into Cancer and Nutrition. ( 30481275 )
2018
42
Primary Non-Hodgkin Lymphoma of Sphenoid Sinus Involving Cavernus Sinus and Clivus with Isolated 3rd Nerve Palsy. ( 30487511 )
2018
43
Pregnancy-related factors and risk of B-cell non-Hodgkin lymphoma among women in Los Angeles. ( 30488431 )
2018
44
Non-Hodgkin lymphoma risk in adults living with HIV across five continents. ( 30407252 )
2018
45
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. ( 30409718 )
2018
46
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma. ( 30410083 )
2018
47
Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway. ( 30423319 )
2018
48
The acceleration of CAR-T therapy in non-Hodgkin lymphoma. ( 30427551 )
2018
49
Aggressive squamous cell carcinoma as a harbinger of non-Hodgkin lymphoma. ( 30306113 )
2018
50
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma. ( 30310789 )
2018

Variations for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

75
# Symbol AA change Variation ID SNP ID
1 BRAF p.Gly469Ala VAR_018620 rs121913355
2 BRAF p.Gly469Arg VAR_018622 rs121913357
3 BRAF p.Asp594Gly VAR_018624 rs121913338
4 CASP10 p.Ala414Val VAR_037430 rs28936699

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

6 (show top 50) (show all 110)
# Gene Variation Type Significance SNP ID Assembly Location
1 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh37 Chromosome 8, 95403868: 95403868
2 RAD54B NM_012415.3(RAD54B): c.1778A> G (p.Asn593Ser) single nucleotide variant Pathogenic rs114216685 GRCh38 Chromosome 8, 94391640: 94391640
3 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh37 Chromosome 1, 46738430: 46738430
4 RAD54L NM_001142548.1(RAD54L): c.1331T> A (p.Val444Glu) single nucleotide variant Pathogenic rs121908689 GRCh38 Chromosome 1, 46272758: 46272758
5 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh37 Chromosome 2, 202074111: 202074111
6 CASP10 NM_032977.3(CASP10): c.1241C> T (p.Ala414Val) single nucleotide variant Pathogenic rs28936699 GRCh38 Chromosome 2, 201209388: 201209388
7 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh37 Chromosome 2, 202070652: 202070652
8 CASP10 NM_032977.3(CASP10): c.769C> T (p.Gln257Ter) single nucleotide variant Pathogenic rs121909775 GRCh38 Chromosome 2, 201205929: 201205929
9 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh37 Chromosome 2, 202073912: 202073913
10 CASP10 NM_032977.3(CASP10): c.1042_1043insA (p.Gly348Glufs) insertion Pathogenic rs398122800 GRCh38 Chromosome 2, 201209189: 201209190
11 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
12 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
13 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
14 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
15 TP53 NM_000546.5(TP53): c.974G> T (p.Gly325Val) single nucleotide variant Uncertain significance rs121912659 GRCh37 Chromosome 17, 7576872: 7576872
16 TP53 NM_000546.5(TP53): c.974G> T (p.Gly325Val) single nucleotide variant Uncertain significance rs121912659 GRCh38 Chromosome 17, 7673554: 7673554
17 PRF1 NM_001083116.2(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh37 Chromosome 10, 72358355: 72358355
18 PRF1 NM_001083116.2(PRF1): c.1122G> A (p.Trp374Ter) single nucleotide variant Pathogenic rs104894176 GRCh38 Chromosome 10, 70598599: 70598599
19 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
20 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh38 Chromosome 1, 114716124: 114716124
21 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
22 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
23 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
24 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 GRCh38 Chromosome 7, 140781603: 140781603
25 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
26 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 GRCh38 Chromosome 7, 140781602: 140781602
27 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
28 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh38 Chromosome 7, 140753354: 140753354
29 MYD88 NM_002468.4(MYD88): c.794T> C (p.Leu265Pro) single nucleotide variant Uncertain significance rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
30 MYD88 NM_002468.4(MYD88): c.794T> C (p.Leu265Pro) single nucleotide variant Uncertain significance rs387907272 GRCh38 Chromosome 3, 38141150: 38141150
31 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
32 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
33 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 NCBI36 Chromosome 7, 148139660: 148139660
34 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
35 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
36 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 NCBI36 Chromosome 7, 148139661: 148139661
37 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
38 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
39 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
40 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
41 TP53 NM_000546.5(TP53): c.845G> A (p.Arg282Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730882008 GRCh37 Chromosome 17, 7577093: 7577093
42 TP53 NM_000546.5(TP53): c.845G> A (p.Arg282Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs730882008 GRCh38 Chromosome 17, 7673775: 7673775
43 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
44 NRAS NM_002524.4(NRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh38 Chromosome 1, 114716123: 114716123
45 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh37 Chromosome 15, 66727455: 66727455
46 MAP2K1 NM_002755.3(MAP2K1): c.171G> C (p.Lys57Asn) single nucleotide variant Likely pathogenic rs869025608 GRCh38 Chromosome 15, 66435117: 66435117
47 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
48 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
49 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
50 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635

Cosmic variations for Lymphoma, Non-Hodgkin, Familial:

9 (show all 31)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44623 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
2 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.581T>G p.L194R 17:7674950-7674950 9
3 COSM10894 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.670G>A p.E224K 17:7674861-7674861 9
4 COSM35908 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2251G>A p.E751K 6:137881197-137881197 9
5 COSM35907 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 9
6 COSM35911 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1354G>T p.E452* 6:137878799-137878799 9
7 COSM35970 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.1421C>A p.T474N 6:137878866-137878866 9
8 COSM35913 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.905T>C p.L302P 6:137877175-137877175 9
9 COSM35969 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.503G>A p.W168* 6:137875704-137875704 9
10 COSM35909 TNFAIP3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.254G>A p.W85* 6:137871481-137871481 9
11 COSM6987354 STAG2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3688A>G p.M1230V 23:124100589-124100589 9
12 COSM6945907 PIM1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.94G>A p.E32K 6:37170784-37170784 9
13 COSM6975552 PAX5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.559A>T p.I187F 9:37002693-37002693 9
14 COSM581 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.181C>G p.Q61E 1:114713909-114713909 9
15 COSM586 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.183A>C p.Q61H 1:114713907-114713907 9
16 COSM562 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.34G>T p.G12C 1:114716127-114716127 9
17 COSM564 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>A p.G12D 1:114716126-114716126 9
18 COSM574 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.38G>T p.G13V 1:114716123-114716123 9
19 COSM566 NRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.35G>T p.G12V 1:114716126-114716126 9
20 COSM5416033 NFKBIE haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.782+5G>A p.? 6:44264977-44264977 9
21 COSM499 HRAS haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.182A>G p.Q61R 11:533874-533874 9
22 COSM6987350 ARID5B haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.793T>G p.F265V 10:62050947-62050947 9
23 COSM307270 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.208T>A p.Y70N 17:7675125-7675125 9
24 COSM307267 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
25 COSM307268 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
26 COSM3717662 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9
27 COSM6987351 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.64T>G p.F22V 10:62050947-62050947 9
28 COSM6987353 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.3799A>G p.M1267V 23:124100589-124100589 9
29 COSM307269 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.91T>A p.Y31N 17:7675125-7675125 9
30 COSM3077774 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.295T>C p.C99R 6:394899-394899 9
31 COSM3717661 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.487T>A p.Y163N 17:7675125-7675125 9

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 164351 22 36286416 36295356 Translate CEP1 Non-Hodgkin''s lymphomas

Expression for Lymphoma, Non-Hodgkin, Familial

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 BCL10 BCL6 BRAF CASP10 CCND1 IRF4
2
Show member pathways
13.34 BCL6 BRAF CCND1 IRF4 MYC NRAS
3
Show member pathways
13.22 BCL10 BRAF CCND1 MYC NRAS PTPRC
4
Show member pathways
13.07 CASP10 CCND1 MYC NRAS PIK3CA TP53
5
Show member pathways
12.86 BRAF CCND1 MYC NRAS PIK3CA TP53
6 12.8 ALK BRAF CCND1 MYC NRAS PIK3CA
7
Show member pathways
12.76 ALK BRAF CCND1 NRAS PIK3CA TP53
8
Show member pathways
12.76 CASP10 IRF4 MYC NRAS PIK3CA PRF1
9
Show member pathways
12.75 BRAF CCND1 MYC NRAS PIK3CA TP53
10
Show member pathways
12.72 BRAF NPM1 NRAS PIK3CA TP53
11 12.56 BCL10 BCL6 IRF4 PAX5 PTPRC
12 12.51 CCND1 MYC NRAS PIK3CA TP53
13
Show member pathways
12.48 CCND1 MYC NRAS PIK3CA
14
Show member pathways
12.44 CASP10 NRAS PIK3CA TP53
15
Show member pathways